NMN Supplements in 2026: The Longevity Powder Britain’s Biohackers Swear By – And Where the Evidence Actually Stands

A tub of powder that promises to slow down ageing shouldn’t cost less than a decent bottle of gin, and yet here we are. The longevity aisle has a new favourite, and last autumn it got the closest thing to an official blessing it’s ever had. In September 2025 the US Food and Drug Administration quietly reversed its own position and confirmed that NMN can be sold as a dietary supplement after all – three years after it looked ready to pull it off American shelves. British buyers took that as a green light. The problem is that the actual science hasn’t moved nearly as fast as the marketing, and here in the UK the legal picture is messier than any brand wants you to know.

So it’s worth slowing down before you tap “add to basket”.

What NMN supplements actually are

NMN is nicotinamide mononucleotide, and it’s a precursor to something called NAD+ – a molecule every cell in your body uses to turn food into energy and to run repair processes. NAD+ levels fall as we age. That decline is real and well documented, and it’s the entire basis for the NMN supplements industry: top up the precursor, the theory goes, and you top up the NAD+, and your cells behave a little younger.

It’s a clean story. The biology underneath it is genuinely interesting, and the researchers involved aren’t cranks – this came out of serious labs, not a wellness influencer’s kitchen. It’s the same pattern we’ve seen with every longevity darling, from berberine’s “nature’s Ozempic” billing to the mushroom nootropics: a real mechanism, then a marketing department that runs miles ahead of the data. NAD+ sits at the centre of metabolism, and the idea that restoring it could push back against age-related decline has kept molecular biologists busy for years.

But a precursor raising a molecule in your bloodstream is not the same thing as that molecule making you live longer, or even feel better. That gap – between mechanism and outcome – is where most of the NMN story falls apart, and it’s the bit the £60 tubs skip over.

The one human study everyone quotes

Ask a shop assistant or read the back of a jar and you’ll eventually hit the same reference: a 2021 trial published in Science. It’s the study that launched a thousand product pages, so it’s worth knowing what it actually did.

Researchers at Washington University in St Louis gave 250mg of NMN a day to a group of postmenopausal women with prediabetes, for ten weeks, against a placebo. The finding: NMN improved muscle insulin sensitivity – roughly, the muscles got better at responding to insulin and taking up glucose. That’s a meaningful result for metabolic health, and it was the first proper look at NMN’s effects in people.

Now the part the marketing leaves out. Thirteen women took NMN. Twelve took the placebo. Twenty-five people, all of them postmenopausal, all of them prediabetic. It’s a small, specific study in a specific group – not proof that a healthy 40-year-old bloke buying it for “energy and longevity” will get anything at all. And the study measured a metabolic marker in muscle tissue. It did not measure lifespan, wrinkles, energy levels, or anything you can feel. The researchers themselves said more work was needed before anyone claimed NMN prevents or manages diabetes.

One good small study is a reason to keep researching. It isn’t a reason to spend £700 a year.

It’s worth being clear about what insulin sensitivity even is, because the marketing tends to blur it into “anti-ageing” and hope you don’t ask. When your muscles are insulin sensitive, they respond well to the hormone and pull sugar out of your blood efficiently. That matters most if you’re heading towards type 2 diabetes, which is exactly the group the study picked. For a metabolically healthy person with normal blood sugar, there’s no reason to think you’ve got the same headroom to improve – you can’t fix a problem you don’t have. So the one positive human result is, on its own terms, least relevant to the healthy under-50s who make up most of NMN’s actual customers.

What the newer trials found – and it’s not what the tubs claim

The reliable finding across human trials is narrow: NMN does raise blood NAD+ levels. Take it and your circulating NAD+ goes up, sometimes close to double. On that one point the evidence is solid, and the safety record is reassuring too – trials have used doses up to 1,200mg a day without serious side effects. That’s better than a lot of the supplement shelf, where the dose in the tub often doesn’t match the label – as the lab testing on creatine gummies found, four in six had almost no active ingredient at all.

And then the story runs into a wall. A 2025 meta-analysis pooling ten randomised controlled trials looked at whether NMN improved muscle mass, strength or physical function in older adults. It found no benefit. None of the outcomes people actually buy the stuff for – feeling stronger, moving better, ageing slower – showed up when you added the trials together.

This is the central awkwardness of NMN. It does exactly what it says on the biochemical level and almost nothing you’d notice on the human level. The dramatic results – mice on NMN running further, looking younger, living longer – keep failing to reproduce in people. Mice aren’t small humans, and a raised blood marker isn’t a health benefit until a trial shows it changes something that matters.

There’s a reason the mouse work looks so much better, and it’s not sinister – it’s just biology. Lab mice are bred to be genetically near-identical, kept in identical cages, fed identical food, and dosed at levels that, scaled to bodyweight, dwarf what a human takes from a capsule. Their whole physiology is different, their lifespans are measured in months, and the “ageing” you can reverse in a two-year-old mouse doesn’t map neatly onto a 55-year-old who’s had five decades of real life. Nearly every anti-ageing compound that’s ever excited the newspapers started with a spectacular mouse result. Most of them got quietly smaller as the trials got more human.

That’s not a reason to dismiss the research. It’s a reason to read the promising early findings as promising early findings, not as a settled case that justifies a standing order.

My honest read: if you’re taking NMN and feel more energetic, that’s worth being suspicious of, not celebrating. There’s no trial evidence it does that, which makes a felt “boost” far more likely to be placebo, better sleep, or the fact that people who spend £60 on longevity powder tend to also start going for walks and cutting the wine.

The bit no brand will tell you: it’s not properly legal here

Here’s where British buyers should pay attention. In the UK, NMN is classed as a novel food – a food or ingredient with no significant history of consumption before 1997 – and novel foods need safety assessment and formal authorisation from the Food Standards Agency before they can be sold as supplements. NMN hasn’t got that authorisation. It sits “under assessment” on the regulator’s books.

In plain terms: NMN isn’t currently authorised to be sold as a food supplement in Great Britain. It isn’t banned or illegal to possess, and enforcement is patchy enough that you can order it from a dozen UK websites this afternoon. But the products lining up to sell it to you are in a regulatory grey zone, and none of them can legally make a health claim – they can’t tell you it treats, prevents or slows anything, because no such claim has been approved.

The novel food rule isn’t bureaucratic pedantry, either. It exists because “people have been eating this for centuries” is a genuine safety signal, and NMN in pill form is new – we’ve only been swallowing concentrated doses of it for a handful of years. The assessment the FSA is running is the boring, sensible work of checking that a novel concentrated compound is safe at the doses people actually take, over years, not weeks. That the answer will probably turn out fine doesn’t mean the question was silly.

That’s a very different situation from the US, where the FDA’s September 2025 decision cleared NMN as a lawful supplement ingredient. The American U-turn made headlines and a lot of British brands rode the wave. But the FDA doesn’t regulate what’s sold in Sheffield or Cardiff, and the FSA hasn’t reached the same conclusion. If a UK seller is quoting the FDA reversal at you as reassurance, they’re borrowing someone else’s homework.

NR, the quieter rival

NMN isn’t the only NAD+ booster on the shelf, and it sits in a crowded corner of the wellness aisle next to the nootropic mushrooms and the sleep stacks. Its main competitor is nicotinamide riboside, or NR, which has actually been through the novel food process in some markets and has its own pile of human trials. NR reliably raises NAD+ too. And it runs into the same problem as NMN – the blood marker goes up, the meaningful health outcomes mostly don’t.

A human trial that compared NAD+ precursors head to head found they all lifted NAD+ to varying degrees, which is a bit like discovering that several different taps all produce water. The interesting question was never whether these compounds raise NAD+. It’s whether raising NAD+ in a middle-aged human body does anything you’d pay for. On that, NR and NMN are in the same boat, bailing with the same small bucket.

The price, and the halo it borrows

Let’s talk money, because it’s the part that should sting. A month of NMN at the doses the studies used – 250mg to around 900mg a day – runs you somewhere between £30 and £70 depending on brand and format, and the fancier ones with clean third-party testing sit at the top of that. Call it £600 to £800 a year for a powder whose only proven effect is nudging a number in your blood.

Part of what you’re paying for is the halo. NMN got famous because a small group of very visible longevity obsessives built their whole personal brand around it – the sort who publish their biomarkers online and spend six figures a year trying to reverse their biological age. When a tech millionaire takes something at breakfast and tells the internet he’s ageing backwards, it lends the whole category a glow that the trial data can’t. And the tubs are designed to keep that glow going: frosted glass, minimalist labels, words like “cellular” and “NAD+ optimisation” that sound clinical without promising anything a regulator could pin them on.

If you do buy, the one thing genuinely worth paying for is a certificate of analysis – independent lab testing showing the tub contains what the label says, at the purity it claims. NMN degrades if it’s stored badly, and it’s an expensive enough ingredient that adulteration is a real risk. A brand that won’t show you a batch test is one to walk past.

What about the drips and patches?

If a £60 tub feels too pedestrian, the wellness clinics have you covered. NAD+ intravenous drips have crept into British aesthetic clinics and “longevity” studios over the last couple of years, usually pitched at £200 to £400 a session and sold as a faster, more complete way to flood the body with NAD+. Some clients report a warm flush and a burst of clarity during the infusion. Others describe an hour of feeling faintly sick with a cannula in their arm.

Here’s my problem with them. The human evidence for oral NMN is thin; the human evidence that an NAD+ drip does anything more than an oral dose, for anything you’d actually notice, is thinner still. You’re paying a large premium for the theatre of a clinic and a drip stand. The transdermal patches are worse value again – the dose that crosses intact skin is tiny, and there’s no good trial showing a patch moves NAD+ in any meaningful way. If you’ve decided to experiment with NAD+, the cheap oral powder is the sensible place to start, not the £300 infusion.

Where your £60 is better spent

If the goal is the thing NMN is sold on – keeping your body metabolically younger for longer – the unglamorous options have vastly better evidence behind them, and most of them are free.

Exercise, and resistance training in particular, does measurably improve insulin sensitivity, muscle mass and physical function in older adults – the exact outcomes the 2025 NMN meta-analysis couldn’t find. The NHS recommends adults do strengthening activity on at least two days a week alongside 150 minutes of moderate activity, and unlike NMN there’s no debate about whether it works. Sleep and not being sedentary do more for your cellular health than any powder – the magnesium-for-sleep crowd and the electrolyte drinkers could stand to hear the same thing. If it’s the NAD+ angle you’re chasing, your body already makes NAD+ from ordinary dietary niacin – vitamin B3 – found in meat, fish, eggs and wholegrains, the kind of thing you get from a normal week of eating without a frosted-glass jar in sight.

I’m not saying NMN does nothing. I’m saying the current evidence supports one claim – it raises a blood marker – and the industry is charging longevity prices for it. That’s the gap you’re paying to ignore.

So who, if anyone, is it for? If you’re a well-off longevity enthusiast who’s already nailed the free stuff – you train, you sleep, you eat properly, your bloods are good – and you’ve got money you’re happy to gamble on an unproven bet, NMN is safe enough to try and you can afford to be wrong. That’s a narrow slice of people. For everyone else – anyone hoping a supplement will paper over a diet of takeaways and a desk job, or anyone on a budget who has to choose where their health money goes – it’s the wrong place to spend. The honest answer isn’t “it works” or “it’s a scam”. It’s “it does one measurable thing, we don’t yet know if that thing matters, and you’re paying as though we do”.

If you’re set on trying it anyway, go in clear-eyed: buy from a seller that shows third-party testing, ignore any health claim on the label because none of them are authorised here, and treat it as an experiment on yourself, not medicine. Give it three months, and be honest about whether you actually feel different or just feel like you should, given what it cost.

The longevity field will eventually get the large, long human trials that settle this – some are running now. Until then, the most age-slowing thing you can do with an NMN budget might be to spend it on a decent pair of trainers. What would it take for you to believe a supplement was worth £700 a year – and has anything you’ve bought ever cleared that bar?